

PRESS RELEASE
Uppsala
May 20, 2009

Q-Med introduces two new Restylane® products with lidocaine

Q-Med is proud to announce Restylane® Lidocaine and Restylane Perlane™ Lidocaine as the latest additions to the Restylane range. Frown lines, wrinkles around the nose, mouth and between the eyes can be quickly managed with the new products Restylane Lidocaine and Restylane Perlane Lidocaine. Through the addition of 0.3 percent lidocaine the products offer maximum effect with a minimum of discomfort during treatment.

Lidocaine is a swift and safe local anaesthetic that is widely used by physicians to numb treatment sites. Since we all experience pain differently, it is a comfort to have the choice of a Restylane treatment with integrated pain relief.

The results from a randomised, double-blind, split face study shows that 90 percent of the subjects assessed Restylane Perlane Lidocaine as being the more comfortable treatment with regard to pain at injection when compared to injection without the addition of lidocaine. The filler effect was shown in the same study to be equivalent to the corresponding product without lidocaine.

“The Restylane family of products is among the world’s most widely used dermal fillers. With Restylane Lidocaine and Restylane Perlane Lidocaine consumers can now get rid of any unwanted wrinkles and experience more comfort during a treatment that is quick, safe and long lasting” says Bengt Ågerup, founder and CEO of Q-Med.

The Restylane gel is a crystal-clear gel based on stabilized hyaluronic acid. Hyaluronic acid is found naturally in the skin with the main function to bind water. Bengt Ågerup has patented the unique NASHA™ technology, which stabilizes hyaluronic acid, making it last longer and at the same time be similar to the body’s own hyaluronic acid.

Restylane has been on the market for more than 12 years and is the most extensively studied dermal filler in the world. To date, more than 10 million treatments have been performed and a large number of scientific studies, including more than 10 randomized clinical trials, have been published in peer reviewed journals. Restylane has, in a recent study, proven effect lasting up to 18 months with one retreatment.

Queries should be addressed to:

Bengt Ågerup, President and CEO

Tel: +46 70 974 9025

Alexander Kotsinas, Vice President and CFO

Tel: +46 735 00 1111

Q-Med AB is a medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta™** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 650 coworkers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web: www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.